Overview
Diagnostics company's Q4 revenue rose 1%, beating analyst expectations
Company's core test reports increased 42% in Q4, driven by dermatologic and gastrointestinal tests
Outlook
Castle Biosciences anticipates 2026 revenue between $340 mln and $350 mln
Result Drivers
CORE TEST GROWTH - Total test reports for DecisionDx-Melanoma and TissueCypher increased 37% over 2024, with TissueCypher reports growing 86%
MEDICARE COVERAGE IMPACT - Revenue affected by change in DecisionDx-SCC Medicare coverage and discontinuation of IDgenetix
Company press release: ID:nGNX4v36tf
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $87.01 mln | $79.05 mln (7 Analysts) |
Q4 Net Income | -$2.33 mln | ||
Q4 Operating Expenses | $90.84 mln | ||
Q4 Operating Income | -$3.83 mln | ||
Q4 Pretax Profit | -$2.71 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Castle Biosciences Inc is $50.00, about 62.2% above its February 25 closing price of $30.83
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)